LZVS developer Arvato has prepared the next Core release 1.11, which will replace the current version 1.10. With the new version of the Core release, several functional changes and improvements will be introduced, including SSO (single sing out) functionality improvements, as well as system security enhancements.

The European Medicines Verification Organization (EMVO) has launched a newsletter, which informs about the National Medicines Verification Organization (NMVO) and the European Change Control Board (EU CCB) created by the EMVO, various working groups – IT, quality, as well as the Inter-Operability Testing group, which allows for more efficient management of the medicines verification system and improvement of its development in all Member States.

The Latvian Medicines Verification Organization (LZVO) held three seminars on the current affairs of the Medicines Verification System in Latvia in September, directly addressing and informing more than 130 participants from 117 companies.

Latvijas Zāļu verifikācijas organizācija (LZVO) septembrī rīkoto bezmaksas semināru ciklu noslēdza ar diviem semināriem gala lietotājiem par zāļu verifikācijas sistēmas aktualitātēm Latvijā.

Latvijas Zāļu verifikācijas organizācija (LZVO) septembrī rīkoja bezmaksas semināru ražotājiem par Zāļu verifikācijas sistēmas aktualitātēm Latvijā, tieši uzrunājot un informējot 40 dalībniekus no 34 uzņēmumiem.

Lai informētu visus savus partnerus – gan zāļu ražotājus, gan verifikācijas sistēmas gala lietotājus – par sistēmas aktualitātēm, Latvijas Zāļu verifikācijas organizācija (LZVO) 2022. gada septembrī rīko trīs semināru ciklu. Visi semināri būs bezmaksas pasākumi.

The Latvian Medicines Verification Organization (LZVO) in the second issue of the Newsletter (July 2022) informs about system news, the planned informative events in autumn, LZVS performance indicators in the first half of 2022 and analyse received alerts in the system.

In the first half of the year in Latvia, 13,7 million medicine packages were checked against falsification from the medicines purchased by citizens in pharmacies or used by patients in healthcare institutions. This is 10% more than in the first six months of last year.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.20)”.